ATE206162T1 - Chemotaktisches protein - Google Patents

Chemotaktisches protein

Info

Publication number
ATE206162T1
ATE206162T1 AT94917388T AT94917388T ATE206162T1 AT E206162 T1 ATE206162 T1 AT E206162T1 AT 94917388 T AT94917388 T AT 94917388T AT 94917388 T AT94917388 T AT 94917388T AT E206162 T1 ATE206162 T1 AT E206162T1
Authority
AT
Austria
Prior art keywords
polypeptide
antagonist
chemotactic protein
inhibitors
inflammation
Prior art date
Application number
AT94917388T
Other languages
English (en)
Inventor
Haodong Li
Steven M Ruben
Granger G Sutton Iii
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE206162T1 publication Critical patent/ATE206162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
AT94917388T 1994-05-16 1994-05-16 Chemotaktisches protein ATE206162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/005384 WO1995031467A1 (en) 1994-05-16 1994-05-16 Monocyte chemotactic protein-4

Publications (1)

Publication Number Publication Date
ATE206162T1 true ATE206162T1 (de) 2001-10-15

Family

ID=22242565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917388T ATE206162T1 (de) 1994-05-16 1994-05-16 Chemotaktisches protein

Country Status (9)

Country Link
EP (1) EP0767796B1 (de)
JP (1) JP3670665B2 (de)
KR (1) KR970703353A (de)
AT (1) ATE206162T1 (de)
AU (1) AU695174B2 (de)
DE (1) DE69428460T2 (de)
NZ (1) NZ266979A (de)
PT (1) PT767796E (de)
WO (1) WO1995031467A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344324T1 (de) * 1993-09-14 2006-11-15 Imp Innovations Ltd Eotaxin = eosinophil chemotaktisches cytokin
US5866373A (en) * 1995-04-21 1999-02-02 Human Genome Sciences, Inc. Polynucleotide encoding a human chemotactic protein
US6100389A (en) * 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
US6075124A (en) * 1994-05-16 2000-06-13 Human Genome Sciences, Inc. Human chemotactin protein
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
WO1997018237A1 (en) * 1995-11-15 1997-05-22 Incyte Pharmaceuticals, Inc. Chemokine from niddm pancreas
AU5355996A (en) * 1996-02-23 1997-09-10 Human Genome Sciences, Inc. Human chemokine polypeptides
GB9617923D0 (en) * 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
US6028169A (en) 1997-03-31 2000-02-22 Human Genome Sciences, Inc. Chemokine β-6 antagonists
ES2187972T3 (es) * 1997-04-04 2003-06-16 Max Planck Gesellschaft Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes.
DE10162869A1 (de) * 2001-12-20 2003-07-31 Alexander Cherkasky Invasive lineare halb-zyklische und zyklische Systeme zur Herauslockung der Krankheitserreger
ATE518884T1 (de) 2002-05-01 2011-08-15 Human Genome Sciences Inc Spezifisch an chemokin beta-4 bindende antikörper
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2669930A1 (fr) * 1990-11-29 1992-06-05 Sanofi Sa Proteine presentant une activite de type cytokine, adn recombinant, vecteur d'expression et hotes permettant son obtention.

Also Published As

Publication number Publication date
KR970703353A (ko) 1997-07-03
EP0767796A4 (de) 1997-06-11
DE69428460D1 (de) 2001-10-31
AU6913094A (en) 1995-12-05
NZ266979A (en) 1999-01-28
WO1995031467A1 (en) 1995-11-23
DE69428460T2 (de) 2002-05-23
JP3670665B2 (ja) 2005-07-13
EP0767796B1 (de) 2001-09-26
AU695174B2 (en) 1998-08-06
PT767796E (pt) 2002-03-28
JPH10500300A (ja) 1998-01-13
EP0767796A1 (de) 1997-04-16

Similar Documents

Publication Publication Date Title
DE69428460D1 (de) Chemotaktisches protein
ATE262914T1 (de) Entzündungsproteine aus makrophagen mip-3, mip-4 und mip-1gamma
DE69533544D1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
DE69418181D1 (de) Cytokine dämpfende substanzen
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
ATE411340T1 (de) Immunregulierer
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
TR199802537T2 (xx) Peptit t�revleri.
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
ATE249835T1 (de) Immunoregulator
DE69632828D1 (de) Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert
NO20050066L (no) Pegylert T20 polypeptid
DK0804465T3 (da) Nye elastaseinhibitorer
DE69535460D1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
FI982198A0 (fi) IL-muteiini
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra
BR9812489A (pt) Uso de 6,7-substituìdas-2-aminotetralinas adequadas para a preparação de uma composição farmacêutica para o tratamento terapêutico de patologias inflamatórias e/ou autoimunes
DK0495721T3 (da) Anvendelsen af et polypeptid med en humant-interleukin-2-aktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af pneumothorax

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee